Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 50.30 as of 2026-10-06T19:16:22.290Z.
Consensus retrieved: 2026-10-06T10:34:07.396Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:16:22.290Z.
Quote observation: 2026-10-06T19:11:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c683fbcf7a5be6196b34cb829f91a73ddbf07994c0e1e68d76d832115efef523
Forward PE Ratio (50.30) = Dated Quote Price ($5.03) / Consensus Forward EPS ($0.10)
FORWARD PE RATIO
50.30
SECTOR MEDIAN · HEALTHCARE
19.84
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+153.53%
vs the sector median at left
Champions Oncology, Inc.
Market Cap
$69.88M
Forward PE Ratio
50.30
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Champions Oncology, Inc. (CSBR) | $69.88M | 50.30 |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.72M | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.19M | N/A |
| Cingulate Inc. (CING)vs › | $66.94M | N/A |
| iBio, Inc. (IBIO)vs › | $66.56M | N/A |
| XBiotech Inc. (XBIT)vs › | $66.01M | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.35M | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $71.64M | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.66M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
50.3
consensus EPS · fiscal year ending 2027-04-30
At the dated quote price of $5.03, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-04-30 | $0.10 | $0.10 – $0.10 | 1 | 50.3x |
| 2028-04-30 | $0.00 | $0.00 – $0.00 | 0 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
